<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Amphotericin B deoxycholate (conventional): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Amphotericin B deoxycholate (conventional): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Amphotericin B deoxycholate (conventional): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11286" href="/d/html/11286.html" rel="external">see "Amphotericin B deoxycholate (conventional): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12647" href="/d/html/12647.html" rel="external">see "Amphotericin B deoxycholate (conventional): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F7254335"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Appropriate use:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">This drug should be used primarily for treatment of patients with progressive and potentially life-threatening fungal infections; it should not be used to treat noninvasive forms of fungal disease such as oral thrush, vaginal candidiasis, and esophageal candidiasis in patients with normal neutrophil counts.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Error prevention:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Exercise caution to prevent inadvertent overdose with amphotericin B. Verify the product name and dosage if dose exceeds 1.5 mg/kg.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865914"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Fungizone IV</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F134709"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antifungal Agent, Parenteral</li></ul></div>
<div class="block doa drugH1Div" id="F134690"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: Formulation:</b> Conventional amphotericin formulations (deoxycholate [Amphocin, Fungizone]) may be confused with lipid-based formulations (AmBisome, Abelcet, Amphotec). Lipid-based and conventional formulations are <b>not</b> interchangeable and have different dosage recommendations. Overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products. <b>Premedication:</b> To minimize infusion-related immediate reactions, premedicate with the following 30 to 60 minutes prior to drug administration: acetaminophen, diphenhydramine, and/or hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022','lexi-content-ref-8838189','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022','lexi-content-ref-8838189','lexi-content-ref-manu.1'])">Ref</a></span>). Preinfusion administration of 1 L of NS may reduce the risk of nephrotoxicity during treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022','lexi-content-ref-manu.1'])">Ref</a></span>). <b>Test dose:</b> A test dose of 1 mg in 20 mL D5W administered over 20 to 30 minutes may be considered.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range: IV:</b> 0.5 to 1 mg/kg/day (range: 0.3 to 1.5 mg/kg/day); maximum dose: 1.5 mg/kg/day. <b>Note:</b> Lipid-based formulations of amphotericin B are generally preferred for treatment of systemic infections because they demonstrate comparable efficacy and better tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31699664','lexi-content-ref-26679628','lexi-content-ref-27365388','lexi-content-ref-17806045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31699664','lexi-content-ref-26679628','lexi-content-ref-27365388','lexi-content-ref-17806045'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e18c5076-0949-4048-928e-a565a8c28714">Aspergillosis, endophthalmitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aspergillosis, endophthalmitis</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Administer a combination of both intraocular (intravitreal and/or intracameral depending on sites of involvement) and systemic (IV or oral) antifungal therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27365388'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intraocular:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Intravitreal injection: For involvement of the vitreous: 5 to 10 mcg per 0.1 mL sterile water as a single intravitreal dose; may be repeated in several days as clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19009680','lexi-content-ref-Durand.2','lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19009680','lexi-content-ref-Durand.2','lexi-content-ref-27365388'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Intracameral injection: For involvement of the aqueous humor: 5 mcg per 0.1 mL sterile water as a single intracameral (into the anterior chamber) dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Durand.2','lexi-content-ref-12352080','lexi-content-ref-17457185']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Durand.2','lexi-content-ref-12352080','lexi-content-ref-17457185'])">Ref</a></span>). <b>Note:</b> May also consider intravitreal injection even if vitritis is not apparent, as occult vitreal involvement is possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Durand.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Durand.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="88c58fcb-77ef-4148-803b-f83c6e2aa28b">Aspergillosis, invasive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aspergillosis, invasive (including disseminated and extrapulmonary) (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Optimal dose not defined; reserve for use in resource-limited settings when no alternatives are available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27365388'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1 to 1.5 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3681380','lexi-content-ref-12167683']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3681380','lexi-content-ref-12167683'])">Ref</a></span>). Minimum treatment duration is 6 to 12 weeks depending on site of infection, extent of disease, and level/duration of immunosuppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27365388'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b66180c1-9659-486b-b77b-bdb1c4096776">Blastomycosis, moderately severe to severe, non-CNS disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Blastomycosis,</b>
<b>moderately severe to severe, non-CNS disease: IV:</b> 0.7 to 1 mg/kg/day for 1 to 2 weeks or until improvement, followed by oral itraconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18462107']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18462107'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a474b86d-f618-403c-abc4-11a9a731c6ce">Candidiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CNS infection (failed to respond to systemic therapy and device removal or when ventricular device cannot be removed) (off-label)<i>: </i>Intraventricular:</b> 0.01 to 0.5 mg per 2 mL of an extemporaneously prepared solution in D5W administered through the device into the ventricle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628','lexi-content-ref-28203777'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Endophthalmitis </b>
<b>(</b>
<b>with or without vitritis):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Administer a combination of both intraocular (intravitreal and/or intracameral depending on sites of involvement) and systemic (IV or oral) antifungal therapy. For patients with endogenous endophthalmitis without vitritis or macular involvement, intraocular antifungals may not be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Durand.1','lexi-content-ref-Durand.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Durand.1','lexi-content-ref-Durand.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Intraocular:</b></p>
<p style="text-indent:-2em;margin-left:10em;">Intravitreal injection: 5 to 10 mcg per 0.1 mL sterile water as a single intravitreal dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>). Intravitreal dose may be repeated in several days if no improvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Durand.1','lexi-content-ref-Durand.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Durand.1','lexi-content-ref-Durand.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Intracameral injection: For exogenous cases involving primarily the aqueous: 5 mcg per 0.1 mL sterile water as a single intracameral (into the anterior chamber) dose. <b>Note:</b> May also consider intravitreal injection even if vitritis is not apparent, as occult vitreal involvement is possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Durand.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Durand.3'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Esophageal, refractory disease (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Reserve use for patients who have inadequate response to or who are unable to take other agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kauffman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kauffman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 0.3 to 0.7 mg/kg/day. Transition to an oral antifungal once patient tolerates oral intake if susceptibility allows; total antifungal duration is 14 to 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022','lexi-content-ref-26679628','lexi-content-ref-Kauffman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022','lexi-content-ref-26679628','lexi-content-ref-Kauffman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Invasive candidiasis (alternative agent): IV:</b> 0.5 to 0.7 mg/kg/day; dose may be increased to as high as 1 mg/kg/day for infections caused by <i>C. glabrata</i> or <i>C. krusei</i>. <b>Note:</b> Given poor tolerability (eg, nephrotoxicity, infusion-related toxicity), experts preferentially recommend lipid formulations when available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oropharyngeal, refractory disease (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Reserve use for patients who have inadequate response to or who are unable to take other agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kauffman.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kauffman.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 500 mg of an extemporaneously compounded 100 mg/mL suspension 3 to 4 times daily for 14 to 28 days; swish in the mouth and retain for as long as possible (several minutes) before swallowing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10839593','lexi-content-ref-26679628','lexi-content-ref-Kauffman.2','lexi-content-ref-10791445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10839593','lexi-content-ref-26679628','lexi-content-ref-Kauffman.2','lexi-content-ref-10791445'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Urinary tract infection (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Candiduria (asymptomatic) in patients undergoing urologic procedures:</i>
<b>IV:</b> 0.3 to 0.6 mg/kg/day for several days before and after the procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Cystitis (symptomatic), fluconazole-resistant species (eg, C. glabrata, C. krusei):</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Bladder irrigation (off-label route): </b>Irrigate with 50 mg amphotericin B deoxycholate diluted in 1 L of sterile water once daily for 5 days. <b>Note:</b> Use of bladder irrigation is generally discouraged, especially in patients who would not otherwise require an indwelling catheter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> 0.3 to 0.6 mg/kg/day for 1 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Fungus balls:</i>
<b>Irrigation via nephrostomy tubes (off-label route):</b> Irrigate with an extemporaneously prepared solution of 25 to 50 mg in 200 to 500 mL sterile water (final concentration range: 0.05 to 0.25 mg/mL); use in combination with systemic antifungal therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Pyelonephritis, fluconazole-resistant species (eg, C. glabrata, C. krusei):</i>
<b>IV:</b> 0.3 to 0.6 mg/kg/day for 1 to 7 days (with or without flucytosine for fluconazole-resistant <i>C. glabrata</i>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Vulvovaginal, caused by <i>C. glabrata</i> (alternative agent) (off-label use): Intravaginal:</b> 3% to 4% extemporaneously compounded cream: 1 applicatorful (~5 g) once daily (at bedtime) for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628','lexi-content-ref-19834757','lexi-content-ref-Sobel.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628','lexi-content-ref-19834757','lexi-content-ref-Sobel.1'])">Ref</a></span>). <b>Note:</b> Reserve for patients with no other clear cause of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sobel.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sobel.1'])">Ref</a></span>). May also be used in combination with intravaginal flucytosine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22648899','lexi-content-ref-20332368','lexi-content-ref-26679628','lexi-content-ref-11402233']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22648899','lexi-content-ref-20332368','lexi-content-ref-26679628','lexi-content-ref-11402233'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7fb5d76c-3366-4cef-be06-02cc83aaddac">Coccidioidomycosis, severe, nonmeningeal infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Coccidioidomycosis, severe, nonmeningeal infection: IV:</b> 0.5 to 1 mg/kg/day until clinical improvement, then switch to an oral azole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022','lexi-content-ref-27470238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022','lexi-content-ref-27470238'])">Ref</a></span>).<b> Note</b>: Some experts suggest initiating the oral azole at the same time as amphotericin B deoxycholate and continuing the oral azole when amphotericin B deoxycholate is discontinued (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ae881309-4d68-4e20-b4b6-a6f947ebc9bb">Cryptococcal meningoencephalitis, disseminated disease, or severe pulmonary disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cryptococcal meningoencephalitis, disseminated disease, or severe pulmonary disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Resource-rich settings </i>
<i>(when a lipid formulation of amphotericin B cannot be used): </i>
<b>IV: </b>Induction therapy: 0.7 to 1 mg/kg/day in combination with flucytosine (preferred) or fluconazole (if flucytosine cannot be used) for ≥2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022','lexi-content-ref-20047480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022','lexi-content-ref-20047480'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Resource-limited settings </i>
<i>(if liposomal amphotericin B is not available) in patients with HIV: </i>
<b>IV:</b> Induction therapy: 1 mg/kg/day in combination with flucytosine for 7 days followed by fluconazole for ≥7 days. <b>Note:</b> If flucytosine is not available, amphotericin B may be given at the same dose in combination with fluconazole for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Who.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Who.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Duration of induction therapy may be extended in patients who cannot use combination therapy or who have evidence of neurological complications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022','lexi-content-ref-20047480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022','lexi-content-ref-20047480'])">Ref</a></span>). Induction therapy is followed by consolidation and maintenance therapy with fluconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30900315','lexi-content-ref-HHS.2022','lexi-content-ref-20047480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30900315','lexi-content-ref-HHS.2022','lexi-content-ref-20047480'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="da0b3cae-9a59-4ae8-9ed2-c6aad13abf2e">Histoplasmosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Histoplasmosis (alternative agent):</b>
<i>Moderately severe to severe pulmonary or disseminated disease</i>: <b>IV:</b> 0.7 to 1 mg/kg/day for 1 to 2 weeks (at least 2 weeks in patients with HIV), followed by oral itraconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddley.1','lexi-content-ref-17806045','lexi-content-ref-12118965']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddley.1','lexi-content-ref-17806045','lexi-content-ref-12118965'])">Ref</a></span>). Some experts prefer to use the higher end of the dosing range (eg, 1 mg/kg/day) in patients with HIV (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddley.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed727c2e-50ad-4916-9de0-8aa740ea0c6a">Leishmaniasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leishmaniasis (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cutaneous</i>: IV: 0.5 to 1 mg/kg/dose once daily or every other day for a total cumulative dose of ~15 to 30 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27941143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27941143'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mucosal</i>: <b>IV</b>: 0.5 to 1 mg/kg/dose once daily or every other day for a total cumulative dose of ~20 to 45 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27941143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27941143'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Visceral (off-label use)</i>: <b>IV:</b> 1 mg/kg/dose once daily or every other day for a total cumulative dose of 15 to 20 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27941143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27941143'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Visceral, patients with HIV (off-label use)</i>: <b>IV:</b> 0.5 to 1 mg/kg/dose once daily for a total cumulative dose of 1,500 to 2,000 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="18253106-69f9-48a9-9c17-2c7df2d5d934">Sporotrichosis, pulmonary, meningeal, osteoarticular, or disseminated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sporotrichosis, </b>
<b>pulmonary, meningeal, osteoarticular, or disseminated</b>: <b>IV:</b> 0.7 to 1 mg/kg/day, followed by oral itraconazole after a favorable response is seen with initial amphotericin therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17968818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17968818'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="49121186-131c-4432-bbd1-93622f3f65b6">Talaromycosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Talaromycosis (formerly penicilliosis) (alternative agent) (off-label use): IV:</b> 0.7 mg/kg/day for 2 weeks (if liposomal amphotericin B unavailable) followed by oral azole consolidation therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990148"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Due to the risks of nephrotoxicity associated with amphotericin B deoxycholate, a conventional amphotericin formulation, only use when benefits outweigh the risks. Lipid-based amphotericin preparations are associated with a lower risk of nephrotoxicity and are preferred in patients with preexisting kidney impairment (including patients on hemodialysis or peritoneal dialysis who have significant residual renal function). If using amphotericin B deoxycholate, limiting dose and duration of treatment (as clinically appropriate), extending infusion time, avoiding concomitant nephrotoxic drugs, and hydration and sodium loading with 1 L of NS prior to starting therapy may reduce the risk of acute kidney injury. Monitor kidney function closely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24204739','lexi-content-ref-1942779','lexi-content-ref-Nemecek.1','lexi-content-ref-15308606','lexi-content-ref-29431860','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24204739','lexi-content-ref-1942779','lexi-content-ref-Nemecek.1','lexi-content-ref-15308606','lexi-content-ref-29431860','lexi-content-ref-manu.1'])">Ref</a></span>). For routes of administration other than IV (eg, intraocular), there are no specific dosage adjustments recommended (has not been studied in patients with kidney impairment); however, need for adjustment is unlikely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Kidney impairment prior to treatment initiation:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function: IV:</b> No dosage adjustment necessary for any degree of kidney impairment (only 2% to 5% excreted in biologically active form) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nemecek.1','lexi-content-ref-21925845','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nemecek.1','lexi-content-ref-21925845','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>): </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Younger patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11382716']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11382716'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Not likely to be significantly dialyzable (highly protein bound with poor peritoneal penetration) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27282851','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27282851','lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b>
<b> IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12615870','lexi-content-ref-19397464','lexi-content-ref-21925845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12615870','lexi-content-ref-19397464','lexi-content-ref-21925845'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Nephrotoxicity during treatment:</b></i> Consider switching to an alternative antifungal agent or a lipid-based amphotericin formulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). However, if continued use of amphotericin B deoxycholate is deemed clinically appropriate, may consider interrupting therapy for 24 to 48 hours, then resume at one-half of the usual daily dose; the dosage may then be increased to the maximally tolerated dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Maddux.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Maddux.1'])">Ref</a></span>). This approach will likely decrease amphotericin deoxycholate exposures, and so should be avoided in the acute phase of serious infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987479"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer’s labeling.</p></div>
<div class="block doo drugH1Div" id="F55170139"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">The recommendations for dosing in patients with obesity are based upon the best available evidence and clinical expertise. Senior Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Class 1, 2, or 3 obesity (BMI ≥30 kg/m<sup>2</sup>): Note:</b> Lipid-based formulations of amphotericin B are generally preferred for treatment of systemic infections because they demonstrate comparable efficacy and better tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31699664','lexi-content-ref-26679628','lexi-content-ref-27365388','lexi-content-ref-17806045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31699664','lexi-content-ref-26679628','lexi-content-ref-27365388','lexi-content-ref-17806045'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>Use <b>adjusted body weight</b> for weight-based dose calculations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>). In more severe infections, may consider using <b>actual body weight</b> for weight-based dose calculations, although this may be associated with increased toxicity due to higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Amsden.1','lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Amsden.1','lexi-content-ref-Expert.DOO'])">Ref</a></span>). When dosing with either<b> adjusted or actual body weight</b>, a maximum daily dose of 150 mg is suggested (extrapolated from a study of a similar product (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31588493','lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31588493','lexi-content-ref-Expert.DOO'])">Ref</a></span>)). Refer to "Dosing: Adult" for indication-specific doses.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Rationale for recommendations:</b> There are sparse data describing the effect of obesity on dosing requirements for polyene antifungals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Amsden.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Amsden.1'])">Ref</a></span>). There are no human pharmacokinetic studies for amphotericin B deoxycholate in patients with obesity. Even though amphotericin B deoxycholate exhibits a V<sub>d</sub> of 2.4 to 5.1 L/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Amsden.1','lexi-content-ref-11801578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Amsden.1','lexi-content-ref-11801578'])">Ref</a></span>), distribution into adipose tissue appears to be limited; therefore, does not support routinely dosing based on actual body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Amsden.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Amsden.1'])">Ref</a></span>). Use <b>adjusted body weight</b> for weight-based dose calculations (expert opinion). For more severe infections, may consider using <b>actual body weight</b> for dose calculations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Amsden.1','lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Amsden.1','lexi-content-ref-Expert.DOO'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F134691"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F134703"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12647" href="/d/html/12647.html" rel="external">see "Amphotericin B deoxycholate (conventional): Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Medication errors, including deaths, have resulted from confusion between lipid-based forms of amphotericin (eg, Abelcet, AmBisome) and amphotericin B deoxycholate (conventional amphotericin B for injection); amphotericin B deoxycholate doses should not exceed 1.5 mg/kg/day.</b> Dose units and presentation (eg, mg/kg, <b>mg</b>, mg/<b>mL</b>, <b>mcg</b>) vary by route of administration (IV, Intrathecal, Intravesical, Intravitreal); use caution.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Premedications: </i>To minimize infusion-related immediate reactions, may premedicate with the following 30 to 60 minutes prior to administration: acetaminophen, diphenhydramine, and/or hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered. Adequate hydration and preinfusion administration of NS may reduce the risk of nephrotoxicity during amphotericin B treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24618932','lexi-content-ref-35849282','lexi-content-ref-HHS.4','lexi-content-ref-HHS.5','lexi-content-ref-17310120','lexi-content-ref-AAP.2','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24618932','lexi-content-ref-35849282','lexi-content-ref-HHS.4','lexi-content-ref-HHS.5','lexi-content-ref-17310120','lexi-content-ref-AAP.2','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: Test dose:</b> Although the manufacturer's labeling suggests a test dose and dose escalation approach, most experts recommend initiation of therapy at the target dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-20536366','lexi-content-ref-HHS.5','lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-20536366','lexi-content-ref-HHS.5','lexi-content-ref-AAP.2'])">Ref</a></span>). A test dose of 1 <b>mg</b> administered over 20 to 30 minutes may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>General dosing:</b></p>
<p style="text-indent:-2em;margin-left:4em;">IV: Infants, Children, and Adolescents: IV: 0.5 to 1 mg/kg/dose once daily; maximum daily dose: 1.5 mg/kg/<b>day</b>. Once therapy has been established, may administer 1.5 mg/kg/dose every other day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Intrathecal, intraventricular, or intracisternal (preferably into the lateral ventricles through a cisternal Ommaya reservoir): Limited data available; dose variable: Infants, Children, and Adolescents: 0.01 to 1 <b>mg</b>; reported frequency varies widely from daily or every other day to twice weekly. Some experts recommend starting with a low dose and gradually increasing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7888533','lexi-content-ref-26679628','lexi-content-ref-28203777','lexi-content-ref-10672422','lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7888533','lexi-content-ref-26679628','lexi-content-ref-28203777','lexi-content-ref-10672422','lexi-content-ref-AAP.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Intravesical: Limited data available: Infants, Children, and Adolescents: 0.05 to 0.1 mg/<b>mL</b> solution, administered as either a continuous bladder irrigation or as an intermittent bladder irrigation (eg, 50 to 100 mL per dwell) every 8 hours with a dwell time of 60 to 90 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-21498839','lexi-content-ref-10554910']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-21498839','lexi-content-ref-10554910'])">Ref</a></span>). Daily administration for 5 days has also been recommended for the treatment of cystitis due to fluconazole-resistant <i>Candida</i> species (<i>C. glabrata</i>, <i>C. krusei</i>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="11922a6f-52e3-4d48-8959-25f730e3f929">Aspergillosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aspergillosis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Endocarditis, treatment (alternative agent)</i>: Children and Adolescents: IV: 1 mg/kg/dose once daily with or without flucytosine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Invasive disease, treatment (alternative agent):</i>
<b>Note: </b>Amphotericin B deoxycholate is not recommended for treatment of invasive aspergillosis except in resource-limited settings when no alternatives are available.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: IV: 1 to 1.5 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30900296','lexi-content-ref-12167683','lexi-content-ref-36978151','lexi-content-ref-22075793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30900296','lexi-content-ref-12167683','lexi-content-ref-36978151','lexi-content-ref-22075793'])">Ref</a></span>). Minimum treatment duration is 6 to 12 weeks depending on site of infection, extent of disease, and level/duration of immunosuppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27365388'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90ff3b27-4e8f-490e-a6d4-4a1a6aab3eca">Blastomycosis, moderately severe to severe disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Blastomycosis, moderately severe to severe disease:</b> Infants, Children, and Adolescents: IV: 0.7 to 1 mg/kg/dose once daily as initial therapy for 1 to 2 weeks, followed by oral itraconazole for a total of 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18462107']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18462107'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="04119584-1974-4656-a3ca-18c3e3348943">Candidiasis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis, treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Invasive</i>: Infants, Children, and Adolescents: IV: 0.5 to 1 mg/kg/dose once daily. Duration should be individualized based on clinical response and presence of deep-tissue foci; isolated candidemia should be treated for ≥14 days from the first negative blood culture and clinical resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Endocarditis</i>: Children and Adolescents: IV: 1 mg/kg/dose once daily with or without flucytosine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>). Step-down to azole therapy in clinically stable patients with susceptible isolates and negative repeat cultures. Total antifungal duration is ≥6 weeks after valve replacement surgery, with longer duration for perivalvular abscess, other complications, or a nonsurgical approach (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Esophageal (alternative agent):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: IV: 0.3 to 0.7 mg/kg/dose once daily; consider step down to an oral antifungal once patient is able to tolerate oral intake. Total treatment duration is 14 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4','lexi-content-ref-HHS.5','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4','lexi-content-ref-HHS.5','lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Oropharyngeal, fluconazole-refractory (alternative agent): </i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: IV: 0.3 mg/kg/dose once daily for 7 to 14 days. Patients with HIV may receive up to 0.5 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5','lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Urinary tract infections:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Asymptomatic candiduria (high-risk patients [eg, patients who are neutropenic]): Infants, Children, and Adolescents: IV: 1 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Cystitis, symptomatic; treatment (<i>Candida krusei or fluconazole-resistant C. glabrata</i>): Infants, Children, and Adolescents: IV: 0.3 to 0.6 mg/kg/dose once daily for 1 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Pyelonephritis, treatment: Infants, Children, and Adolescents: IV: 0.3 to 0.6 mg/kg/dose once daily for 1 to 7 days; consider addition of flucytosine for fluconazole-resistant <i>C. glabrata</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Urologic procedures, prophylaxis in patients with asymptomatic candiduria: Infants, Children, and Adolescents: IV: 0.3 to 0.6 mg/kg/dose once daily for several days before and after procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3b00d09b-403f-403b-bcd2-8c804ff3cf2d">Coccidioidomycosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Coccidioidomycosis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">IV:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Severe disease (eg, non-meningeal disseminated infection, diffuse pulmonary infection):</i> Infants, Children, and Adolescents: IV: 0.5 to 1.5 mg/kg/dose once daily until clinical improvement, then switch to an oral azole to complete a typical treatment duration of ≥12 months, depending on site of infection and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-HHS.4','lexi-content-ref-HHS.5','lexi-content-ref-16206093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-HHS.4','lexi-content-ref-HHS.5','lexi-content-ref-16206093'])">Ref</a></span>). Every-other-day therapy may also be an option (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16206093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16206093'])">Ref</a></span>). <b>Note: </b>Some experts suggest initiating the oral azole in combination with the amphotericin B product and then continuing the oral azole when amphotericin B is discontinued (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4','lexi-content-ref-HHS.5','lexi-content-ref-16206093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4','lexi-content-ref-HHS.5','lexi-content-ref-16206093'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Intrathecal:</p>
<p style="text-indent:-2em;margin-left:6em;">CNS disease: Infants, Children, and Adolescents: Intrathecal: 0.1 to 1.5 <b>mg</b>/dose; frequency ranging from daily to weekly (with or without concomitant azole therapy); initiate at a low dose and increase until intolerance is noted (eg, severe vomiting, exhaustion, or transient dose-related mental status changes); duration determined by clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-16206093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-16206093'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7fde3ff9-c889-4d02-a89e-e555f9474732">Cryptococcal meningoencephalitis, disseminated disease, or severe pulmonary infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cryptococcal meningoencephalitis, disseminated disease, or severe pulmonary infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 0.7 to 1 mg/kg/dose once daily as part of appropriate combination therapy for ≥2 weeks, followed by consolidation therapy with oral fluconazole. For patients with HIV, dose at the higher end of the range. Induction therapy duration may be extended in patients who cannot receive combination therapy, in patients who are clinically deteriorating, if CNS cultures remain positive, or if neurological complications are present. In infants and children with HIV, dose may be increased to 1.5 mg/kg/dose once daily if flucytosine cannot be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20536366','lexi-content-ref-HHS.4','lexi-content-ref-HHS.5','lexi-content-ref-20047480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20536366','lexi-content-ref-HHS.4','lexi-content-ref-HHS.5','lexi-content-ref-20047480'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="53b7bf13-f688-4920-b25f-ba1d2379a560">Endophthalmitis, fungal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endophthalmitis, fungal:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Administer in combination with systemic antifungal therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628','lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628','lexi-content-ref-27365388'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 years and Adolescents: Intravitreal: 5 to 10 <b>mcg </b>of an extemporaneously prepared solution in 0.1 mL sterile water as a single intravitreal dose. Repeat doses separated by 4 to 7 days have been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19009680','lexi-content-ref-33617168','lexi-content-ref-26679628','lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19009680','lexi-content-ref-33617168','lexi-content-ref-26679628','lexi-content-ref-27365388'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="da0b3cae-9a59-4ae8-9ed2-c6aad13abf2e">Histoplasmosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Histoplasmosis (alternative agent):</b>
<i>Moderately severe to severe pulmonary or disseminated disease</i>:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 0.7 to 1 mg/kg/dose once daily for 1 to 2 weeks (at least 2 weeks in patients with HIV), followed by oral itraconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4','lexi-content-ref-HHS.5','lexi-content-ref-17806045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4','lexi-content-ref-HHS.5','lexi-content-ref-17806045'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed727c2e-50ad-4916-9de0-8aa740ea0c6a">Leishmaniasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leishmaniasis (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cutaneous: </i>Infants, Children, and Adolescents: IV: 0.5 to 1 mg/kg/dose daily or every other day for a total cumulative dose of ~15 to 30 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27941143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27941143'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mucosal:</i> Infants, Children, and Adolescents: IV: 0.5 to 1 mg/kg/dose daily or every other day for a total cumulative dose of ~20 to 45 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27941143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27941143'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Visceral: </i>Infants, Children, and Adolescents: IV: 1 mg/kg/dose daily or every other day for a total cumulative dose of ~15 to 20 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30577877','lexi-content-ref-27941143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30577877','lexi-content-ref-27941143'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1762e085-16eb-4d56-91f6-48f0c61ce809">Peritonitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritonitis (CAPD):</b> Limited data available: <b>Note:</b> Amphotericin B has demonstrated poor peritoneal penetration when given systemically, and intraperitoneal administration is associated with abdominal pain and peritoneal irritation; other agents may be preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851742'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Intraperitoneal, dialysate: Infants, Children, and Adolescents: 1 to 4 mg per liter of dialysate has been used in pediatric patients based on case reports and retrospective reviews (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6299987','lexi-content-ref-3767552','lexi-content-ref-17111161','lexi-content-ref-10886585']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6299987','lexi-content-ref-3767552','lexi-content-ref-17111161','lexi-content-ref-10886585'])">Ref</a></span>); lower doses of 0.5 to 3 mg per liter of dialysate have been reported in adults (with or without concomitant systemic amphotericin B therapy); abdominal pain has been associated with doses ≥2 mg per liter of dialysate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3766532','lexi-content-ref-4014323']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3766532','lexi-content-ref-4014323'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Infants, Children, and Adolescents: 1 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11216549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11216549'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="18253106-69f9-48a9-9c17-2c7df2d5d934">Sporotrichosis, pulmonary, meningeal, osteoarticular, or disseminated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sporotrichosis, </b>
<b>pulmonary, meningeal, osteoarticular, or disseminated: </b>Children and Adolescents: IV: 0.7 to 1 mg/kg/dose once daily, then switch to oral itraconazole after a favorable response is seen to complete ≥12 months of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17968818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17968818'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="49121186-131c-4432-bbd1-93622f3f65b6">Talaromycosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Talaromycosis (formerly penicilliosis) (alternative agent):</b> Adolescents with HIV: IV: 0.7 mg/kg/dose once daily for 2 weeks, followed by oral azole consolidation therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51064811"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Mild, moderate, or severe impairment:</b> Infants, Children, and Adolescents: IV: No dosage adjustment necessary for any degree of kidney impairment (only 2% to 5% excreted in biologically active form) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1','lexi-content-ref-Nemecek.1','lexi-content-ref-21925845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1','lexi-content-ref-Nemecek.1','lexi-content-ref-21925845'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent:</b> Not significantly dialyzable (based on adult data) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11382716']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11382716'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: IV: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1','lexi-content-ref-19397464','lexi-content-ref-21925845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1','lexi-content-ref-19397464','lexi-content-ref-21925845'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Not likely to be significantly dialyzable (highly protein bound with poor peritoneal penetration) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27282851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27282851'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: IV: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT: </b></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: IV: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1','lexi-content-ref-19397464','lexi-content-ref-21925845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1','lexi-content-ref-19397464','lexi-content-ref-21925845'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51064812"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F134657"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Systemic:</b></p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, diarrhea, dyspepsia, epigastric pain, nausea, stomach cramps, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Azotemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Normocytic anemia (normochromic)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Pain at injection site (with or without phlebitis or thrombophlebitis)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills, headache, malaise, pain</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Calcium nephrolithiasis, decreased urine specific gravity (hyposthenuria), renal insufficiency, renal tubular acidosis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Tachypnea</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia, flushing, heart failure, hypertension, shock, ventricular fibrillation</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Maculopapular rash, pruritus, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperkalemia, hypocalcemia, hypomagnesemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Hemorrhagic gastroenteritis, melena</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Anuria, oliguria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, disorder of hemostatic components of blood, eosinophilia, leukocytosis, leukopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic<b>: </b>Acute hepatic failure, hepatitis, increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase, increased serum bilirubin, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reactions, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Encephalopathy, leukoencephalopathy, peripheral neuropathy, seizure, vertigo (transient)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Diplopia, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hearing loss, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury, increased blood urea nitrogen, increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, dyspnea, hypersensitivity pneumonitis, pulmonary edema, wheezing</p></div>
<div class="block coi drugH1Div" id="F134672"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to amphotericin or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F134654"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis: Has been reported with amphotericin B-containing drugs; facilities for cardiopulmonary resuscitation should be available during administration due to the possibility of anaphylactic reaction. If severe respiratory distress occurs, the infusion should be immediately discontinued; during the initial dosing, the drug should be administered under close clinical observation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: Acute reactions (eg, fever, rigors, hypotension, anorexia, nausea, vomiting, headache, tachypnea) may occur 1 to 3 hours after starting an intravenous infusion. These reactions are usually more common with the first few doses and generally diminish with subsequent doses. Avoid rapid infusion to prevent hypotension, hypokalemia, arrhythmias, and shock.</p>
<p style="text-indent:-2em;margin-left:4em;">• Leukoencephalopathy: Has been reported following administration of amphotericin B. Total body irradiation has been reported to be a possible predisposition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrotoxicity: May cause nephrotoxicity; risk factors include underlying renal disease, concomitant nephrotoxic medications and daily and/or cumulative dosing of amphotericin. Avoid use with other nephrotoxic drugs; drug-induced renal toxicity usually improves with interrupting therapy, decreasing dosage, or increasing dosing interval. However permanent impairment may occur, especially in patients receiving a large cumulative dose (eg, &gt;5 g) and in those also receiving other nephrotoxic drugs. Hydration and sodium repletion prior to administration may reduce the risk of developing nephrotoxicity. Frequent monitoring of renal function is recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: In a scientific statement from the American Heart Association, amphotericin has been determined to be an agent that may cause direct myocardial toxicity (magnitude: moderate/major) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Patients with neutropenia: Pulmonary reactions may occur in patients with neutropenia receiving leukocyte transfusions; separation of the infusions as much as possible is advised.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Therapy interruption: If therapy is stopped for &gt;7 days, restart at the lowest dose recommended and increase gradually.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878326"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Infusion-related reactions occur less frequently in neonates and infants as compared to children and adolescents; reactions are unlikely to occur in patients &lt;90 days of age (Andrew 2018; Cavassin 2022).</p></div>
<div class="block foc drugH1Div" id="F134665"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as deoxycholate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F134650"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16322986"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Amphotericin B Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $60.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865915"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as deoxycholate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fungizone IV: 50 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F747024"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> May be infused over 2 to 6 hours; an inline filter (≥1 micron mean pore diameter) may be used for administration. To minimize infusion-related immediate reactions, premedicate with the following 30 to 60 minutes prior to drug administration: acetaminophen, diphenhydramine, and/or hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022','lexi-content-ref-8838189','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022','lexi-content-ref-8838189','lexi-content-ref-manu.1'])">Ref</a></span>). Preinfusion administration of 1 L of NS appears to reduce the risk of nephrotoxicity during treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intraocular (off-label route): </b>Administer amphotericin intravitreally or intracamerally with the dose in a final volume in 0.1 mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Durand.2','lexi-content-ref-Durand.1','lexi-content-ref-Durand.3','lexi-content-ref-26679628','lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Durand.2','lexi-content-ref-Durand.1','lexi-content-ref-Durand.3','lexi-content-ref-26679628','lexi-content-ref-27365388'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intraventricular (off-label route):</b> Use preservative-free preparations only. When administered through a ventricular drain, clamp drain for 15 to 60 minutes before opening the drain to allow amphotericin B solution to equilibrate in the CSF (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28203777'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Irrigation (off-label route):</b> A solution for irrigation (final concentration range: 0.05 to 0.25 mg/mL) may be administered via nephrostomy tubes for fungal balls associated with urinary tract infection due to candida. A solution for irrigation (final concentration: 0.05 mg/mL solution) may be instilled via bladder irrigation for cystitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Vaginal (off-</b>
<b>label route):</b> Administer intravaginal cream at bedtime, using an appropriately sized intravaginal applicator to deliver the correct dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19834757','lexi-content-ref-11402233']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19834757','lexi-content-ref-11402233'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52612231"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral:</p>
<p style="text-indent:-2em;margin-left:2em;">IV:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>To minimize immediate infusion-related reactions, may premedicate with the following 30 to 60 minutes prior to administration: acetaminophen, diphenhydramine, and/or hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered. Adequate hydration and preinfusion administration of NS may reduce the risk of nephrotoxicity during amphotericin B treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24618932','lexi-content-ref-35849282','lexi-content-ref-HHS.4','lexi-content-ref-HHS.5','lexi-content-ref-17310120','lexi-content-ref-AAP.2','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24618932','lexi-content-ref-35849282','lexi-content-ref-HHS.4','lexi-content-ref-HHS.5','lexi-content-ref-17310120','lexi-content-ref-AAP.2','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Administer by IV infusion over 2 to 6 hours; an in-line filter (≥1 micron mean pore diameter) may be used for administration. Avoid rapid infusion (eg, &lt;1 hour); associated with hypotension, hypokalemia, arrhythmias, and shock.</p>
<p style="text-indent:-2em;margin-left:4em;">Avoid extravasation; may cause chemical irritation; monitor infusion site; addition of heparin to infusion solution may reduce phlebitis.</p>
<p style="text-indent:-2em;margin-left:2em;">Intrathecal/intraventricular: Administer as diluted solution (0.01 to 1 mg in 2 mL D5W). When administered through a ventricular drain, clamp drain for 15 to 60 minutes to allow solution to equilibrate in the cerebrospinal fluid (CSF) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28203777'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Intravesical (bladder/urinary tract irrigation): Administer as a continuous irrigation or intermittently; has been administered via nephrostomy tubes or into the bladder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29778493','lexi-content-ref-21498839','lexi-content-ref-10554910','lexi-content-ref-26679628','lexi-content-ref-14711869','lexi-content-ref-19910484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29778493','lexi-content-ref-21498839','lexi-content-ref-10554910','lexi-content-ref-26679628','lexi-content-ref-14711869','lexi-content-ref-19910484'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Intravitreal: Administer intravitreally in an appropriate sterile setting by health care professional experienced in administration of intravitreal ophthalmic injections.</p></div>
<div class="block use drugH1Div" id="F134669"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Fungal infection, invasive:</b> Treatment of patients with progressive, potentially life-threatening fungal infections: Aspergillosis, cryptococcosis, North American blastomycosis, systemic candidiasis, coccidioidomycosis, histoplasmosis, zygomycosis (including mucormycosis due to susceptible species of the genera <i>Absidia, Mucor,</i> and <i>Rhizopus</i>), and infections due to related susceptible species of <i>Conidiobolus,</i>
<i>Basidiobolus,</i> and sporotrichosis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Leishmaniasis:</b> Alternative treatment in patients with American (New World) mucocutaneous leishmaniasis</p></div>
<div class="block off-label drugH1Div" id="F25475062"><span class="drugH1">Use: Off-Label: Adult</span><p>Candidiasis, esophageal, refractory disease; Candidiasis, oropharyngeal, refractory disease (oral); Candidiasis, urinary tract; Candidiasis, vulvovaginal, caused by C. glabrata; Leishmaniasis, visceral; Talaromycosis (formerly penicilliosis)</p></div>
<div class="block mst drugH1Div" id="F134718"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Amphotericin B may be confused with amphotericin B liposomal</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Conventional amphotericin formulations (deoxycholate [Amphocin, Fungizone]) may be confused with lipid-based formulations (AmBisome, Abelcet, Amphotec).</p>
<p style="text-indent:-2em;margin-left:4em;">Large overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products. Single daily doses of amphotericin B deoxycholate should not exceed 1.5 mg/kg.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298744"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F134659"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Amphotericin B may enhance the nephrotoxic effect of Aminoglycosides. Amphotericin B may enhance the neurotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arsenic Trioxide: Amphotericin B may enhance the hypotensive effect of Arsenic Trioxide. Amphotericin B may enhance the QTc-prolonging effect of Arsenic Trioxide.  Management: When possible, avoid concurrent use of arsenic trioxide with drugs that can cause electrolyte abnormalities, such as amphotericin B.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Amphotericin B may enhance the adverse/toxic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colistimethate: Amphotericin B may enhance the nephrotoxic effect of Colistimethate.  Management: Avoid coadministration of colistimethate and amphotericin B whenever possible due to the potential for additive or synergistic nephrotoxicity. If coadministration cannot be avoided, closely monitor renal function.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the hypokalemic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Amphotericin B may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Amphotericin B may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: Amphotericin B may enhance the hypokalemic effect of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: May increase the serum concentration of Amphotericin B. Specifically, dronabinol may displace amphotericin B from its protein-binding sites, leading to an increased concentration of active, unbound drug.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flucytosine: Amphotericin B may enhance the adverse/toxic effect of Flucytosine. Amphotericin B may increase the serum concentration of Flucytosine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Foscarnet: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganciclovir-Valganciclovir: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saccharomyces boulardii: Antifungal Agents (Systemic and Oral [Non-Absorbable]) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Amphotericin B may enhance the nephrotoxic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vancomycin: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F13314057"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Amphotericin crosses the placenta and enters the fetal circulation. Amphotericin B is recommended for the treatment of serious systemic fungal diseases in pregnant women. Refer to current guidelines (IDSA [Pappas 2016]; King 1998; Pilmis 2015).</p></div>
<div class="block brc drugH1Div" id="F13314058"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if amphotericin is excreted into breast milk. Due to its poor oral absorption, systemic exposure to the nursing infant is expected to be decreased; however, because of the potential for toxicity, breast-feeding is not recommended by the manufacturer (Mactal-Haaf 2001).</p></div>
<div class="block mop drugH1Div" id="F134663"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">BUN and serum creatinine levels should be determined every other day when therapy is increased and at least weekly thereafter. Renal function (monitor frequently during therapy), electrolytes (especially potassium and magnesium), LFTs, temperature, PT/PTT, CBC; fluid input and output; signs of hypokalemia (muscle weakness, cramping, drowsiness, ECG changes, etc); signs/symptoms of infusion-related reaction (fever, shaking chills, hypotension, anorexia, nausea, vomiting, headache, tachypnea).</p></div>
<div class="block pha drugH1Div" id="F134653"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Binds to ergosterol altering cell membrane permeability in susceptible fungi and causing leakage of cell components with subsequent cell death. Proposed mechanism suggests that amphotericin causes an oxidation-dependent stimulation of macrophages (Lyman 1992).</p></div>
<div class="block phk drugH1Div" id="F134671"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Poor oral absorption</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Concentrations in fluids from inflamed pleura, synovium, and aqueous humor are approximately 2/3 concurrent plasma concentrations; penetration into the vitreous humor or normal amniotic fluids is minimal. Description of penetration into peritoneum varies; may be improved with inflammation (ISPD [Warady 2012]; Li 2016; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">CNS penetration:</p>
<p style="text-indent:-2em;margin-left:6em;">Preterm neonates (GA: 27.4 ± 5 weeks): High interpatient variability; 40% to 90% of serum concentrations (Baley 1990)</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: Poor (inflamed or noninflamed meninges)</p>
<p style="text-indent:-2em;margin-left:6em;">V<sub>d</sub>: Pediatric patients (0 to 18 years): Highly variable; reported range: 0.38 to 3.99 L/kg (Benson 1989; Koren 1988)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding, plasma: 90%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Premature neonates (GA: 27.4 ± 5 weeks): 14.8 hours (range: 5 to 82 hours) (Baley 1990)</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children (4 months to 14 years): 18.1 ± 6.6 hours (range: 11.9 to 40.3 hours) (Benson 1989)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Biphasic: Initial: 15 to 48 hours; Terminal: 15 days</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Within 1 hour following a 4- to 6-hour dose</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (2% to 5% as biologically active form); ~40% eliminated over a 7-day period and may be detected in urine for at least 7 weeks after discontinued use</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance (Benson, 1989):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children (8 months to 9 years): 0.57 ± 0.152 mL/minute/kg</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents (10 to 14 years): 0.24 ± 0.02 mL/minute/kg</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-AAP.2">
<a name="AAP.2"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. Elk Grove Village, IL: American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Amphotericin.1">
<a name="Amphotericin.1"></a>Amphotericin B [prescribing information]. Big Flats, NY: X-Gen Pharmaceuticals; April 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Amphotericin.2">
<a name="Amphotericin.2"></a>Amphotericin B [prescribing information]. Big Flats, NY: X-Gen Pharmaceuticals; October 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Amsden.1">
<a name="Amsden.1"></a>Amsden JR, Slain D. Antifungal dosing in obesity: a review of the literature. <i>Curr Fungal Infect Rep</i>. 2011;5:83-91. doi:10.1007/s12281-011-0049-7</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29352486">
<a name="29352486"></a>Andrew EC, Curtis N, Coghlan B, Cranswick N, Gwee A. Adverse effects of amphotericin B in children; a retrospective comparison of conventional and liposomal formulations. <i>Br J Clin Pharmacol</i>. 2018;84(5):1006-1012. doi:10.1111/bcp.13521<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/29352486/pubmed" id="29352486" target="_blank">29352486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27941143">
<a name="27941143"></a>Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of Leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). <i>Clin Infect Dis</i>. 2016;63(12):1539-1557. doi:10.1093/cid/ciw742<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/27941143/pubmed" id="27941143" target="_blank">27941143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7985716">
<a name="7985716"></a>Arsura EL, Ismail Y, Freedman S, et al, “Amphotericin B-Induced Dilated Cardiomyopathy,” <i>Am J Med</i>, 1994, 97(6):560-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/7985716/pubmed" id="7985716" target="_blank">7985716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17672897">
<a name="17672897"></a>Aydin S, Ertugrul B, Gultekin B, Uyar G, Kir E. Treatment of two postoperative endophthalmitis cases due to <i>Aspergillus flavus</i> and <i>Scopulariopsis</i> spp. with local and systemic antifungal therapy. <i>BMC Infect Dis</i>. 2007;7:87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/17672897/pubmed" id="17672897" target="_blank">17672897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddley.1">
<a name="Baddley.1"></a>Baddley JW. Treatment of histoplasmosis in patients with HIV. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed March 14, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30900315">
<a name="30900315"></a>Baddley JW, Forrest GN; AST Infectious Diseases Community of Practice. Cryptococcosis in solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13543. doi:10.1111/ctr.13543<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/30900315/pubmed" id="30900315" target="_blank">30900315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baley.1">
<a name="Baley.1"></a>Baley JE, Meyers C, Kliegman RM, Jacobs MR, Blumer JL. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. <i>J Pediatr</i>. 1990;116(5):791-797. doi:10.1016/s0022-3476(05)82674-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/2329429/pubmed" id="2329429" target="_blank">2329429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373317">
<a name="26373317"></a>Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis; Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515. doi: 10.1161/CIR.0000000000000298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/26373317/pubmed" id="26373317" target="_blank">26373317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3766532">
<a name="3766532"></a>Bastani B, Westervelt FB Jr. Persistence of Candida despite seemingly adequate systemic and intraperitoneal amphotericin B treatment in a patient on CAPD. <i>Am J Kidney Dis</i>. 1986;8(4):265-266.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/3766532/pubmed" id="3766532" target="_blank">3766532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12615870">
<a name="12615870"></a>Bellmann R, Egger P, Gritsch W, et al. Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltration. <i>J Antimicrob Chemother.</i> 2003;51(3):671-681. doi:10.1093/jac/dkg139<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/12615870/pubmed" id="12615870" target="_blank">12615870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29596222">
<a name="29596222"></a>Benjamin DK Jr, Kaufman DA, Hope WW, et al. A phase 3 study of micafungin versus amphotericin B deoxycholate in infants with invasive candidiasis. <i>Pediatr Infect Dis J</i>. 2018;37(10):992-998. doi:10.1097/INF.0000000000001996<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/29596222/pubmed" id="29596222" target="_blank">29596222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3042267">
<a name="3042267"></a>Benson JM and Nahata MC, “Clinical Use of Systemic Antifungal Agents,” <i>Clin Pharm</i>, 1988, 7(6):424-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/3042267/pubmed" id="3042267" target="_blank">3042267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2610508">
<a name="2610508"></a>Benson JM, Nahata MC. Pharmacokinetics of amphotericin B in children. <i>Antimicrob Agents Chemother</i>. 1989;33(11):1989-1993. doi:10.1128/AAC.33.11.1989<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/2610508/pubmed" id="2610508" target="_blank">2610508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24618932">
<a name="24618932"></a>Bes DF, Rosanova MT, Sberna N, Arrizurieta E. Deoxycholate amphotericin B and nephrotoxicity in the pediatric setting. <i>Pediatr Infect Dis J</i>. 2014;33(8):e198-e206. doi:10.1097/INF.0000000000000299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/24618932/pubmed" id="24618932" target="_blank">24618932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet.</i> 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15173938">
<a name="15173938"></a>Biyikli NK, Tugtepe H, Akpinar I, Alpay H, Ozek E. The longest use of liposomal amphotericin B and 5-fluorocytosine in neonatal renal candidiasis. <i>Pediatr</i>
<i>Nephrol</i>. 2004;19(7):801-804. doi:10.1007/s00467-004-1463-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/15173938/pubmed" id="15173938" target="_blank">15173938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS, Nelson JD, Barnett E, et al. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 29th ed. American Academy of Pediatrics; 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3056312">
<a name="3056312"></a>Branch RA, “Prevention of Amphotericin B-Induced Renal Impairment. A Review on the Use of Sodium Supplementation,” <i>Arch Intern Med</i>, 1988, 148(11):2389-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/3056312/pubmed" id="3056312" target="_blank">3056312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3681380">
<a name="3681380"></a>Burch PA, Karp JE, Merz WG, Kuhlman JE, Fishman EK. Favorable outcome of invasive aspergillosis in patients with acute leukemia. <i>J Clin Oncol</i>. 1987;5(12):1985-1993. doi:10.1200/JCO.1987.5.12.1985<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/3681380/pubmed" id="3681380" target="_blank">3681380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>Candidiasis (Mucocutaneous). In: US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf</a>. Updated May 26, 2020. Accessed June 16, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35849282">
<a name="35849282"></a>Cavassin FB, Baú-Carneiro JL, de Araújo Motta F, Ville APM, Staszczak L, de Queiroz-Telles F. Amphotericin B in pediatrics: analysis by age stratification suggests a greater chance of adverse events from 13 months of age onwards. <i>Paediatr Drugs</i>. 2022;24(5):513-528. doi:10.1007/s40272-022-00523-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/35849282/pubmed" id="35849282" target="_blank">35849282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19009680">
<a name="19009680"></a>Chakrabarti A, Shivaprakash MR, Singh R, et al. Fungal endophthalmitis: fourteen years' experience from a center in India. <i>Retina</i>. 2008;28(10):1400-1407. doi:10.1097/iae.0b013e318185e943<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/19009680/pubmed" id="19009680" target="_blank">19009680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22648899">
<a name="22648899"></a>Challenor R, Pinsent S, Ekanayaka R. A case series of the management of symptomatic azole-resistant candida. <i>Int J STD AIDS</i>. 2012;23(5):375-376. doi:10.1258/ijsa.2009.009441<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/22648899/pubmed" id="22648899" target="_blank">22648899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18462107">
<a name="18462107"></a>Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2008;46(12):1801-1812.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/18462107/pubmed" id="18462107" target="_blank">18462107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29778493">
<a name="29778493"></a>Chen CW, Hsu CH, Sheu JC, et al. Retrograde ureteral catheterization: a possible new treatment for renal fungal balls in very low birth weight infants. <i>Urology</i>. 2018;120:234-237. doi:10.1016/j.urology.2018.05.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/29778493/pubmed" id="29778493" target="_blank">29778493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7888533">
<a name="7888533"></a>Chiou CC, Wong TT, Lin HH, et al. Fungal infection of ventriculoperitoneal shunts in children. <i>Clin Infect Dis</i>. 1994;19(6):1049-1053. doi:10.1093/clinids/19.6.1049<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/7888533/pubmed" id="7888533" target="_blank">7888533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31699664">
<a name="31699664"></a>Cornely OA, Alastruey-Izquierdo A, Arenz D, et al; Mucormycosis ECMM MSG Global Guideline Writing Group. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. <i>Lancet Infect Dis</i>. 2019;19(12):e405-e421. doi:10.1016/S1473-3099(19)30312-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/31699664/pubmed" id="31699664" target="_blank">31699664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1497007">
<a name="1497007"></a>Cruz JM, Peacock JE Jr, Loomer L, et al, “Rapid Intravenous Infusion of Amphotericin B: A Pilot Study,” <i>Am J Med</i>, 1992, 93:123-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/1497007/pubmed" id="1497007" target="_blank">1497007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7566587">
<a name="7566587"></a>Devuyst O, Goffin E, and Van Ypersele de Strihou C, “Recurrent Hemiparesis Under Amphotericin B for <i>Candida albicans</i> Peritonitis,” <i>Nephrol Dial Transplant</i>, 1995, 10(5):699-701.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/7566587/pubmed" id="7566587" target="_blank">7566587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11801578">
<a name="11801578"></a>Dupont B. Overview of the lipid formulations of amphotericin B. <i>J Antimicrob Chemother</i>. 2002;49(suppl 1):S31-S36. doi:10.1093/jac/49.suppl_1.31<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/11801578/pubmed" id="11801578" target="_blank">11801578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Durand.1">
<a name="Durand.1"></a>Durand ML, Kauffman CA. Treatment of endogenous endophthalmitis due to Candida species. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed March 10, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Durand.2">
<a name="Durand.2"></a>Durand ML, Kauffman CA. Treatment of endophthalmitis due to molds. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed March 10, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Durand.3">
<a name="Durand.3"></a>Durand ML, Kauffman CA. Treatment of exogenous endophthalmitis due to Candida species. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed March 10, 2022c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33617168">
<a name="33617168"></a>El Hamichi S, Kon Graversen V, Gold AS, Berrocal AM, Murray TG. Case report: endogenous Candida endophthalmitis in Cornelia de Lange syndrome: atypical stellate neuroretinitis. <i>Optom Vis Sci</i>. 2021;98(2):104-108. doi:10.1097/OPX.0000000000001639<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/33617168/pubmed" id="33617168" target="_blank">33617168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11238151">
<a name="11238151"></a>Eriksson U, Seifert B, and Schaffner A, "Comparison of Effects of Amphotericin B Deoxycholate Infused Over 4 or 24 Hours: Randomised Controlled Trial," <i>BMJ</i>, 2001, 322(7286):579-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/11238151/pubmed" id="11238151" target="_blank">11238151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24204739">
<a name="24204739"></a>Falagas ME, Karageorgopoulos DE, Tansarli GS. Continuous versus conventional infusion of amphotericin B deoxycholate: a meta-analysis.<i> PLoS One.</i> 2013;8(10):e77075. doi:10.1371/journal.pone.0077075<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/24204739/pubmed" id="24204739" target="_blank">24204739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10839593">
<a name="10839593"></a>Fichtenbaum CJ, Zackin R, Rajicic N, Powderly WG, Wheat LJ, Zingman BS. Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection. Adult AIDS Clinical Trials Group Study Team 295. <i>AIDS</i>. 2000;14(7):845-852. doi:10.1097/00002030-200005050-00011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/10839593/pubmed" id="10839593" target="_blank">10839593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21498839">
<a name="21498839"></a>Fisher JF, Sobel JD, Kauffman CA, et al. Candida urinary tract infections – treatment. <i>Clin Infect Dis</i>. 2011;52(Suppl 6):S457-S466.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/21498839/pubmed" id="21498839" target="_blank">21498839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7655137">
<a name="7655137"></a>Gales MA and Gales BJ, “Rapid Infusion of Amphotericin B in Dextrose,” <i>Ann Pharmacother</i>, 1995, 29(5):523-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/7655137/pubmed" id="7655137" target="_blank">7655137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16206093">
<a name="16206093"></a>Galgiani JN, Ampel NM, Blair JE, et al; Infectious Diseases Society of America. Coccidioidomycosis. <i>Clin Infect Dis</i>. 2005;41(9):1217-1223. doi: 10.1086/496991.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/16206093/pubmed" id="16206093" target="_blank">16206093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27470238">
<a name="27470238"></a>Galgiani JN, Ampel NM, Blair JE, et al. 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. <i>Clin Infect Dis</i>. 2016;63(6):e112-e146. doi:10.1093/cid/ciw360<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/27470238/pubmed" id="27470238" target="_blank">27470238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2184499">
<a name="2184499"></a>Gallis HA, Drew RH, and Pickard WW, “Amphotericin B: 30 Years of Clinical Experience,” <i>Rev Infect Dis</i>, 1990, 12(2):308-29.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/2184499/pubmed" id="2184499" target="_blank">2184499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7795069">
<a name="7795069"></a>Goodwin SD, Cleary JD, Walawander CA, et al, “Pretreatment Regimens for Adverse Events Related to Infusion of Amphotericin B,” <i>Clin Infect Dis</i>, 1995, 20(4):755-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/7795069/pubmed" id="7795069" target="_blank">7795069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22086858">
<a name="22086858"></a>Gould FK, Denning DW, Elliott TS, et al, “Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,” <i>J Antimicrob Chemother</i>, 2012, 67(2):269-89.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/22086858/pubmed" id="22086858" target="_blank">22086858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10554910">
<a name="10554910"></a>Gubbins PO, McConnell SA, and Penzak SR, "Current Management of Funguria," <i>Am J Health Syst Pharm</i>, 1999, 56(19):1929-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/10554910/pubmed" id="10554910" target="_blank">10554910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11382716">
<a name="11382716"></a>Gussak HM, Rahman S, Bastani B. Administration and clearance of amphotericin B during high-efficiency or high-efficiency/high-flux dialysis. <i>Am J Kidney Dis.</i> 2001;37(6):E45. doi:10.1053/ajkd.2001.24545<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/11382716/pubmed" id="11382716" target="_blank">11382716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20536366">
<a name="20536366"></a>Hamill RJ, Sobel JD, El-Sadr W, et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. <i>Clin Infect Dis</i>. 2010;51(2):225-232. doi:10.1086/653606<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/20536366/pubmed" id="20536366" target="_blank">20536366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11705428">
<a name="11705428"></a>Harbarth S, Pestotnik SL, Lloyd JF, et al, "The Epidemiology of Nephrotoxicity Associated With Conventional Amphotericin B Therapy," <i>Am J Med</i>, 2001, 111(7):528-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/11705428/pubmed" id="11705428" target="_blank">11705428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30577877">
<a name="30577877"></a>Hasnain MG, Nath P, Maruf S, et al. Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study. <i>BMC Res Notes</i>. 2018;11(1):918. doi:10.1186/s13104-018-4036-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/30577877/pubmed" id="30577877" target="_blank">30577877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy</i>. 2009;29(5):562-577. doi:10.1592/phco.29.5.562<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12167683">
<a name="12167683"></a>Herbrecht R, Denning DW, Patterson TF, et al; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. <i>N Engl J Med</i>. 2002;347(6):408-415. doi:10.1056/NEJMoa020191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/12167683/pubmed" id="12167683" target="_blank">12167683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20332368">
<a name="20332368"></a>Hettiarachchi N, Ashbee HR, Wilson JD. Prevalence and management of non-albicans vaginal candidiasis. <i>Sex Transm Infect</i>. 2010;86(2):99-100. doi:10.1136/sti.2009.040386<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/20332368/pubmed" id="20332368" target="_blank">20332368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23278539">
<a name="23278539"></a>Hoenigl M, Krause R. Antifungal therapy of aspergillosis of the central nervous system and aspergillus endophthalmitis. <i>Curr Pharm Des</i>.2013;19(20):3648-3668.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/23278539/pubmed" id="23278539" target="_blank">23278539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6299987">
<a name="6299987"></a>Hogg RJ, Arant BS Jr, Houser MT. Candida peritonitis in children on continuous ambulatory peritoneal dialysis. <i>Int J Pediatr Nephrol</i>. 1982;3(4):287-291.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/6299987/pubmed" id="6299987" target="_blank">6299987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30900296">
<a name="30900296"></a>Husain S, Camargo JF. Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13544. doi:10.1111/ctr.13544<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/30900296/pubmed" id="30900296" target="_blank">30900296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12684904">
<a name="12684904"></a>Imhof A, Walter RB, and Schaffner A, "Continuous Infusion of Escalated Doses of Amphotericin B Deoxycholate: An Open-Label Observational Study," <i>Clin Infect Dis</i>, 2003, 36(8):943-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/12684904/pubmed" id="12684904" target="_blank">12684904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12118965">
<a name="12118965"></a>Johnson PC, Wheat LJ, Cloud GA, et al; U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. <i>Ann Intern Med</i>. 2002;137(2):105-109. doi:10.7326/0003-4819-137-2-200207160-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/12118965/pubmed" id="12118965" target="_blank">12118965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4014323">
<a name="4014323"></a>Johnson RJ, Ramsey PG, Gallagher N, Ahmad S. Fungal peritonitis in patients on peritoneal dialysis: incidence, clinical features and prognosis. <i>Am J Nephrol</i>. 1985;5(3):169-175.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/4014323/pubmed" id="4014323" target="_blank">4014323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jones.1">
<a name="Jones.1"></a>Jones RS, Barman A, Suh B, et al, “Successful Treatment of <i>Aspergillus vertebral</i> Osteomyelitis With Amphotericin B Lipid Complex,” <i>Infect Dis Clin Pract</i>, 1995, 4:237-9.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17968818">
<a name="17968818"></a>Kauffman CA, Bustamante B, Chapman SW, Pappas PG, Infectious Diseases Society of America. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2007;45(10):1255-1265.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/17968818/pubmed" id="17968818" target="_blank">17968818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kauffman.1">
<a name="Kauffman.1"></a>Kauffman CA. Esophageal candidiasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed September 23, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kauffman.2">
<a name="Kauffman.2"></a>Kauffman CA. Oropharyngeal candidiasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed June 17, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11588423">
<a name="11588423"></a>Kaushik S, Ram J, Brar GS, Jain AK, Chakraborti A, Gupta A. Intracameral amphotericin B: initial experience in severe keratomycosis. <i>Cornea</i>. 2001;20(7):715-719.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/11588423/pubmed" id="11588423" target="_blank">11588423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31586424">
<a name="31586424"></a>Kim J, Nakwa FL, Araujo Motta F, et al. A randomized, double-blind trial investigating the efficacy of caspofungin versus amphotericin B deoxycholate in the treatment of invasive candidiasis in neonates and infants younger than 3 months of age. <i>J Antimicrob Chemother.</i> 2020;75(1):215-220. doi:10.1093/jac/dkz398<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/31586424/pubmed" id="31586424" target="_blank">31586424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9827262">
<a name="9827262"></a>King CT, Rogers PD, Cleary JD, et al, "Antifungal Therapy During Pregnancy," <i>Clin Infect Dis</i>, 1998, 27(5):1151-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/9827262/pubmed" id="9827262" target="_blank">9827262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1595747">
<a name="1595747"></a>Kintzel PE and Smith GH, “Practical Guidelines for Preparing and Administering Amphotericin B,” <i>Am J Hosp Pharm</i>, 1992, 49(5):1156-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/1595747/pubmed" id="1595747" target="_blank">1595747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10318297">
<a name="10318297"></a>Klaus JR, Knodel LC, Kavanagh RE. Administration guidelines for parenteral drug therapy. Part I: pediatric patients. <i>J Pharm Technol</i>. 1989;5(3):101-128. doi:10.1177/875512258900500306<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/10318297/pubmed" id="10318297" target="_blank">10318297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3411404">
<a name="3411404"></a>Koren G, Lau A, Klein J, et al. Pharmacokinetics and adverse effects of amphotericin B in infants and children. <i>J Pediatr</i>. 1988;113(3):559-563. doi:10.1016/s0022-3476(88)80653-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/3411404/pubmed" id="3411404" target="_blank">3411404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3767552">
<a name="3767552"></a>Kravitz SP, Berry PL. Successful treatment of Aspergillus peritonitis in a child undergoing continuous cycling peritoneal dialysis. <i>Arch Intern Med</i>. 1986;146(10):2061-2062.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/3767552/pubmed" id="3767552" target="_blank">3767552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14711869">
<a name="14711869"></a>Ku JH, Kim ME, Jeon YS, et al, "Urinary Ascites and Anuria Caused by Bilateral Fungal Balls in a Premature Infant," <i>Arch Dis Child Fetal Neonatal Ed</i>, 2004, 89(1):F92-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/14711869/pubmed" id="14711869" target="_blank">14711869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12352080">
<a name="12352080"></a>Kuriakose T, Kothari M, Paul P, Jacob P, Thomas R. Intracameral amphotericin B injection in the management of deep keratomycosis. <i>Cornea</i>. 2002;21(7):653-656. doi:10.1097/00003226-200210000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/12352080/pubmed" id="12352080" target="_blank">12352080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27282851">
<a name="27282851"></a>Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. <i>Perit Dial Int</i>. 2016;36(5):481-508. doi:10.3747/pdi.2016.00078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/27282851/pubmed" id="27282851" target="_blank">27282851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1942779">
<a name="1942779"></a>Llanos A, Cieza J, Bernardo J, et al. Effect of salt supplementation on amphotericin B nephrotoxicity. <i>Kidney Int.</i> 1991;40(2):302-308. doi:10.1038/ki.1991.214<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/1942779/pubmed" id="1942779" target="_blank">1942779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1379913">
<a name="1379913"></a>Lyman CA and Walsh TJ, “Systemically Administered Antifungal Agents. A Review of Their Clinical Pharmacology and Therapeutic Applications,” <i>Drugs</i>, 1992, 44(1):9-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/1379913/pubmed" id="1379913" target="_blank">1379913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11847833">
<a name="11847833"></a>Mactal-Haaf C, Hoffman M, and Kuchta A, "Use of Anti-infective Agents During Lactation, Part 3: Antivirals, Antifungals, and Urinary Antiseptics," <i>J Hum Lact</i>, 2001, 17(2):160-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/11847833/pubmed" id="11847833" target="_blank">11847833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Maddux.1">
<a name="Maddux.1"></a>Maddux MS, Barriere SL. A review of complications of amphotericin-B therapy: recommendations for prevention and management. <i>Drug Intelligence &amp; Clinical Pharmacy.</i> 1980;14(3):177-181. doi:10.1177/106002808001400303</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19910484">
<a name="19910484"></a>Martinez-Pajares JD, Martinez-Ferriz MC, Moreno-Perez D, Garcia-Ramirez M, Martin-Carballido S, Blanch-Iribarne P. Management of obstructive renal failure caused by bilateral renal aspergilloma in an immunocompetent newborn. <i>J Med Microbiol</i>. 2010;59(Pt 3):367-369. doi:10.1099/jmm.0.012799-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/19910484/pubmed" id="19910484" target="_blank">19910484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1448317">
<a name="1448317"></a>Maxson S, Miller SF, Tryka AF, Schutze GE. Perinatal blastomycosis: a review. <i>Pediatr Infect Dis J</i>. 1992;11(9):760-763. doi:10.1097/00006454-199209000-00016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/1448317/pubmed" id="1448317" target="_blank">1448317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18447660">
<a name="18447660"></a>Mohr J, Johnson M, Cooper T, et al, “Current Options in Antifungal Pharmacotherapy,” <i>Pharmacotherapy</i>, 2008, 28(5):614-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/18447660/pubmed" id="18447660" target="_blank">18447660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10672422">
<a name="10672422"></a>Murphy K, Bradley J, James HE. The treatment of <i>Candida albicans</i> shunt infections. <i>Childs Nerv Syst</i>. 2000;16(1):4-7. doi:10.1007/s003810050002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/10672422/pubmed" id="10672422" target="_blank">10672422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17310120">
<a name="17310120"></a>Nath CE, McLachlan AJ, Shaw PJ, Coakley JC, Earl JW. Amphotericin B dose optimization in children with malignant diseases. <i>Chemotherapy</i>. 2007;53(2):142-147. doi:10.1159/000100013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/17310120/pubmed" id="17310120" target="_blank">17310120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nemecek.1">
<a name="Nemecek.1"></a>Nemecek BD, Hammond DA, eds. <i>Demystifying Drug Dosing in Renal Dysfunction</i>. American Society of Health-System Pharmacists; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10344610">
<a name="10344610"></a>Nesbit SA, Ketz KE, McClain BW, et al. Comparison of two concentrations of amphotericin B bladder irrigation in the treatment of funguria in patients with indwelling urinary catheters. <i>Am J Health Syst Pharm</i>. 1999;56(9):872- 875.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/10344610/pubmed" id="10344610" target="_blank">10344610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26679628">
<a name="26679628"></a>Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;62(4):e1-e50. doi: 10.1093/cid/civ933.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/26679628/pubmed" id="26679628" target="_blank">26679628</a>]</span>
<span class="doi">10.1093/cid/civ933</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9868423">
<a name="9868423"></a>Patel R, “Antifungal Agents. Part I. Amphotericin B Preparations and Flucytosine,” <i>Mayo Clin Proc</i>, 1998, 73(12):1205-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/9868423/pubmed" id="9868423" target="_blank">9868423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27365388">
<a name="27365388"></a>Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;63(4):e1-e60. doi:10.1093/cid/ciw326<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/27365388/pubmed" id="27365388" target="_blank">27365388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15308606">
<a name="15308606"></a>Peleg AY and Woods ML. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. <i>J Antimicrob Chemother.</i> 2004;54(4):803-808.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/15308606/pubmed" id="15308606" target="_blank">15308606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20047480">
<a name="20047480"></a>Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2010;50(3):291-322.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/20047480/pubmed" id="20047480" target="_blank">20047480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25204341">
<a name="25204341"></a>Pilmis B, Jullien V, Sobel J, et al. Antifungal drugs during pregnancy: an updated review. <i>J Antimicrob Chemother</i>. 2015;70(1):14-22. doi: 10.1093/jac/dku355.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/25204341/pubmed" id="25204341" target="_blank">25204341</a>]</span>
<span class="doi">10.1093/jac/dku355</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36704126">
<a name="36704126"></a>Puertas Sanjuan A, Parramón-Teixidó CJ, Hernandez-Perez S, Frick MA, Cabañas Poy MJ. Persistent dyselectrolytemia in a neonate induced by liposomal amphotericin B. A case report. <i>Front Pediatr.</i> 2023;10:1099305. doi:10.3389/fped.2022.1099305<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/36704126/pubmed" id="36704126" target="_blank">36704126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17111161">
<a name="17111161"></a>Raaijmakers R, Schröder C, Monnens L, Cornelissen E, Warris A. Fungal peritonitis in children on peritoneal dialysis. <i>Pediatr Nephrol</i>. 2007;22(2):288-293. doi:10.1007/s00467-006-0289-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/17111161/pubmed" id="17111161" target="_blank">17111161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-583082">
<a name="583082"></a>Rao HK, Myers GJ. Candida meningitis in the newborn. <i>South Med J.</i> 1979;72(11):1468-1471. doi:10.1097/00007611-197911000-00036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/583082/pubmed" id="583082" target="_blank">583082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1536590">
<a name="1536590"></a>Rehan VK, Davidson DC. Neonatal renal candidal bezoar. <i>Arch Dis Child</i>. 1992;67(1 Spec No):63-64. doi:10.1136/adc.67.1_spec_no.63<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/1536590/pubmed" id="1536590" target="_blank">1536590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7935701">
<a name="7935701"></a>Rex JH, Bennett JE, Sugar AM, “A Randomized Trial Comparing Fluconazole With Amphotericin B for the Treatment of Candidemia in Patients Without Neutropenia. Candidemia Study Group and the National Institute,” <i>N Engl J Med</i>, 1994, 331(20):1325-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/7935701/pubmed" id="7935701" target="_blank">7935701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21239843">
<a name="21239843"></a>Riddell J 4th, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. <i>Clin Infect Dis</i>. 2011;52(5):648-653. doi: 10.1093/cid/ciq204.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/21239843/pubmed" id="21239843" target="_blank">21239843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11978476">
<a name="11978476"></a>Ritterband D, Kelly J, McNamara T, Kresloff M, Koplin R, Seedor J. Delayed-onset multifocal polymicrobial keratitis after laser in situ keratomileusis. <i>J Cataract Refract Surg</i>. 2002;28(5):898-899.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/11978476/pubmed" id="11978476" target="_blank">11978476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29431860">
<a name="29431860"></a>Rothenbühler C, Held U, Manz MG, Schanz U, Gerber B. Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia.<i> Hematol Oncol</i>. 2018;36(2):471-480. doi:10.1002/hon.2500<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/29431860/pubmed" id="29431860" target="_blank">29431860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2702348">
<a name="2702348"></a>Shapiro S, Javed T, Mealey J Jr. Candida albicans shunt infection. <i>Pediatr Neurosci.</i> 1989;15(3):125-130.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/2702348/pubmed" id="2702348" target="_blank">2702348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8838189">
<a name="8838189"></a>Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. <i>Clin Infect Dis</i>. 1996;22(2):315-321.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/8838189/pubmed" id="8838189" target="_blank">8838189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21925845">
<a name="21925845"></a>Sinnollareddy M, Peake SL, Roberts MS, Lipman J, Roberts JA. Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review.<i> Int J Antimicrob Agents.</i> 2012;39(1):1-10. doi:10.1016/j.ijantimicag.2011.07.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/21925845/pubmed" id="21925845" target="_blank">21925845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19834757">
<a name="19834757"></a>Sivasubramanian G, Sobel JD. Refractory urinary tract and vulvovaginal infection caused by Candida krusei. <i>Int Urogynecol J Pelvic Floor Dysfunct</i>. 2009;20(11):1379-1381. doi:10.1007/s00192-009-0869-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/19834757/pubmed" id="19834757" target="_blank">19834757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10221369">
<a name="10221369"></a>Slain D, “Lipid-Based Amphotericin B for the Treatment of Fungal Infections,” <i>Pharmacotherapy</i>, 1999, 19(3):306-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/10221369/pubmed" id="10221369" target="_blank">10221369</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sobel.1">
<a name="Sobel.1"></a>Sobel JD. Candida vulvovaginitis: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 27, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11740828">
<a name="11740828"></a>Stevens DA and Shatsky SA, "Intrathecal Amphotericin in the Management of Coccidioidal Meningitis," <i>Semin Respir Infect</i>, 2001, 16(4):263-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/11740828/pubmed" id="11740828" target="_blank">11740828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10791445">
<a name="10791445"></a>Taillandier J, Esnault Y, Alemanni M. A comparison of fluconazole oral suspension and amphotericin B oral suspension in older patients with oropharyngeal candidosis. Multicentre Study Group. <i>Age Ageing.</i> 2000;29(2):117-123. doi:10.1093/ageing/29.2.117<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/10791445/pubmed" id="10791445" target="_blank">10791445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12072733">
<a name="12072733"></a>Tamcelik N, Ozdamar A, Kizilkaya M, Devranoglu K, Ustundag C, Demirkesen C. Fungal keratitis after nonpenetrating glaucoma surgery. <i>Cornea</i>. 2002;21(5):532-534.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/12072733/pubmed" id="12072733" target="_blank">12072733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36978151">
<a name="36978151"></a>Terlizzi V, Motisi MA, Pellegrino R, Galli L, Taccetti G, Chiappini E. Management of pulmonary aspergillosis in children: a systematic review. <i>Ital J Pediatr</i>. 2023;49(1):39. doi:10.1186/s13052-023-01440-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/36978151/pubmed" id="36978151" target="_blank">36978151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2488376">
<a name="2488376"></a>The Ad Hoc Advisory Panel on Peritonitis Management. “Continuous Ambulatory Peritoneal Dialysis (CAPD) Peritonitis Treatment Recommendations: 1989 Update,” <i>Perit Dial Int</i>, 1989, 9(4):247-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/2488376/pubmed" id="2488376" target="_blank">2488376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22075793">
<a name="22075793"></a>Tragiannidis A, Roilides E, Walsh TJ, Groll AH. Invasive aspergillosis in children with acquired immunodeficiencies. <i>Clin Infect Dis</i>. 2012;54(2):258-267. doi:10.1093/cid/cir786<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/22075793/pubmed" id="22075793" target="_blank">22075793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28203777">
<a name="28203777"></a>Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. <i>Clin Infect Dis</i>. 2017;64(6):e34-e65. doi:10.1093/cid/ciw861<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/28203777/pubmed" id="28203777" target="_blank">28203777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19082636">
<a name="19082636"></a>Turcu R, Patterson MJ, Omar S. Influence of sodium intake on amphotericin B-induced nephrotoxicity among extremely premature infants. <i>Pediatr Nephrol</i>. 2009;24(3):497-505. doi:10.1007/s00467-008-1050-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/19082636/pubmed" id="19082636" target="_blank">19082636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21301335">
<a name="21301335"></a>Turkova A, Roilides E, Sharland M. Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy - is there a 'right' choice? <i>Curr Opin Infect Dis</i>. 2011;24(2):163-171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/21301335/pubmed" id="21301335" target="_blank">21301335</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet.</i> 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.4">
<a name="HHS.4"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf</a>. Updated 2023. Accessed May 25, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2022">
<a name="HHS.2022"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf</a>. Updated January 12, 2022. Accessed March 2, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.3">
<a name="HHS.3"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Children with and Exposed to HIV. Guidelines for the prevention and treatment of opportunistic infections in children with and exposed to HIV. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-oi/guidelines-pediatric-oi.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-oi/guidelines-pediatric-oi.pdf</a>. Updated September 2, 2022. Accessed May 25, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.5">
<a name="HHS.5"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Children with and Exposed to HIV. Guidelines for the prevention and treatment of opportunistic infections in children with and exposed to HIV. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new</a>. Updated September 14, 2023. Accessed October 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VON.1">
<a name="VON.1"></a>Vermont Oxford Network (VON). Neonatal drug concentrations. Updated November 2022. Accessed August 10, 2023. https://public.vtoxford.org/neonatal-drug-concentrations
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9543603">
<a name="9543603"></a>Visser D, Monnens L, Feitz W, Semmekrot B. Fungal bezoars as a cause of renal insufficiency in neonates and infants--recommended treatment strategy. <i>Clin Nephrol.</i> 1998;49(3):198-201.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/9543603/pubmed" id="9543603" target="_blank">9543603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851742">
<a name="22851742"></a>Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. <i>Perit Dial Int</i>. 2012;32 Suppl 2:S32-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/22851742/pubmed" id="22851742" target="_blank">22851742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10886585">
<a name="10886585"></a>Warady BA, Bashir M, Donaldson LA. Fungal peritonitis in children receiving peritoneal dialysis: a report of the NAPRTCS. <i>Kidney Int</i>. 2000a;58(1):384-389.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/10886585/pubmed" id="10886585" target="_blank">10886585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11216549">
<a name="11216549"></a>Warady BA, Schaefer F, Holloway M, et al. Consensus guidelines for the treatment of peritonitis in pediatric patients receiving peritoneal dialysis. <i>Perit Dial Int</i>, 2000b;20(6):610-624.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/11216549/pubmed" id="11216549" target="_blank">11216549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31588493">
<a name="31588493"></a>Wasmann RE, Smit C, van Dongen EPH, et al. Fixed dosing of liposomal amphotericin B in morbidly obese individuals. <i>Clin Infect Dis</i>. 2020;70(10):2213-2215. doi:10.1093/cid/ciz885<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/31588493/pubmed" id="31588493" target="_blank">31588493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17806045">
<a name="17806045"></a>Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2007;45(7):807-825.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/17806045/pubmed" id="17806045" target="_blank">17806045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11402233">
<a name="11402233"></a>White DJ, Habib AR, Vanthuyne A, Langford S, Symonds M. Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections. <i>Sex Transm Infect</i>. 2001;77(3):212-213. doi:10.1136/sti.77.3.212<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/11402233/pubmed" id="11402233" target="_blank">11402233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Who.1">
<a name="Who.1"></a>World Health Organization (WHO). Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. https://www.who.int/publications/i/item/9789240052178. Published June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1746578">
<a name="1746578"></a>Wiest DB, Maish WA, Garner SS, el-Chaar GM. Stability of amphotericin B in four concentrations of dextrose injection. <i>Am J Hosp Pharm</i>. 1991;48(11):2430-2433.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/1746578/pubmed" id="1746578" target="_blank">1746578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17457185">
<a name="17457185"></a>Yilmaz S, Ture M, Maden A. Efficacy of intracameral amphotericin B injection in the management of refractory keratomycosis and endophthalmitis. <i>Cornea</i>. 2007;26(4):398-402.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/17457185/pubmed" id="17457185" target="_blank">17457185</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34664853">
<a name="34664853"></a>Yuan L, Chen F, Sun Y, Zhang Y, Ji X, Jin B. Candida meningitis in an infant after abdominal surgery successfully treated with intrathecal and intravenous amphotericin B: a case report. <i>Medicine (Baltimore)</i>. 2021;100(37):e27205. doi:10.1097/MD.0000000000027205<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/34664853/pubmed" id="34664853" target="_blank">34664853</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8701 Version 278.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
